Items Tagged ‘Precision Cancer Medicine’

June 25, 2018

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

By

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP inhibitor to standard chemotherapy improved overall response rates and delayed cancer progression in patients […]

View full entry

Tags: Lung Cancer, Lung Cancer - Small Cell, News, PARP Inhibitor Treatment, Precision Cancer Medicine, small cell lung cancer


June 22, 2018

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

By

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause […]

View full entry

Tags: immunotherapy, keytruda, Lung Cancer, News, nsclc, pembrolizumab, Precision Cancer Medicine, squamous non–small-cell lung cancer


June 4, 2018

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers

By

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About LOXO-202 LOXO-292 is an oral precision cancer medicine that is designed to target cancers with genomic […]

View full entry

Tags: loxo 292, loxo oncology, lung, Lung Cancer, News, pancreatic, Precision Cancer Medicine, RET Fusion, Thyroid Cancer


May 23, 2018

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.   Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin’s lymphoma (NHL), […]

View full entry

Tags: Aliqopa, CHRONOS-1 clinical study, copanlisib, follicular non-hodgkin lymphoma, News, Non-Hodgkin's Lymphoma, Precision Cancer Medicine


May 16, 2018

PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer

By

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in New Orleans, Louisiana.  Preliminary results from the study suggest that the combination could provide meaningful […]

View full entry

Tags: checkpoint inhibitor, News, Ovarian Cancer, PARP Inhibitors, PD-1, Precision Cancer Medicine


April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


April 5, 2018

Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma

By

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1 About Melanoma  Metastatic melanoma refers to skin cancer that has spread from […]

View full entry

Tags: BRAF 600, Mekinist rametinib, Melanoma, Metastatic melanoma treatment, News, Precision Cancer Medicine, Skin Cancer, Tafinlar (dabrafenib)


April 4, 2018

Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer

By

CancerConnect News: Combination therapy with Afinitor (everolimus) and Femara (letrozole) demonstrated encouraging activity in the treatment of advanced endometrial cancer, according to a report from the Society of Gynecologic Oncologists meeting this week. About Uterine (Endometrial) Cancer Uterine cancer is one of the most common gynecologic cancers in women, with more than 67,000 individuals diagnosed […]

View full entry

Tags: afinitor, endometrial cancer treatment, Femara, mtor, News, Precision Cancer Medicine, Uterine Cancer, uterine cancer treatment


March 28, 2018

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma

By

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.1 “There are significant knowledge gaps about multiple myeloma, and among […]

View full entry

Tags: abbvie, Multiple Myeloma, myeloma treatment, News, Precision Cancer Medicine


March 22, 2018

FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the successful outcome of the ECHELON-1 clinical trial that compared Adcetris plus AVD (Adriamycin, vinblastine and dacarbazine) to ABVD […]

View full entry

Tags: adcetris, brentuximab, classical, hodgkin lymphoma, Hodgkin's Lymphoma, News, Precision Cancer Medicine, vedotin


March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


March 1, 2018

Managing a rare cancer

By

Managing a rare cancer diagnosis presents unique challenges. One survivor shares her tips for navigating the sometimes-murky waters. CancerConnect News: Happy New Year: January 7  (the day I became really special). On January 7, I became really special. The pathologist at Good Samaritan Medical Center in West Palm Beach, Florida, where I had been hospitalized […]

View full entry

Tags: General, genomics, News, Precision Cancer Medicine, rare cancers


March 1, 2018

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma

By

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death, or the need for additional therapy, compared with patients who received the standard treatment for advanced HL.1 Hodgkin’s lymphoma is […]

View full entry

Tags: ABVD, adcetris, brentuximab, hodgkin lymphoma, Hodgkin's Lymphoma, News, Precision Cancer Medicine, vedotin


February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News, Pancreatic Cancer, Precision Cancer Medicine, treatment


February 26, 2018

Keytruda Improves Survival of Advanced Bladder Cancer

By

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary Cancer Symposium.1 About Bladder Cancer Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, treatment